4/A: Clover Health CEO Amends RSU Vesting Disclosure, Reflecting Full Performance Achievement
Insider Transaction Amendment
Clover Health's CEO of Home Care, Brady Priest, amended a Form 4 filing to clarify the full achievement and vesting of performance-based restricted stock units.
Summary
- Brady Patrick Priest, CEO of Home Care at Clover Health Investments, Corp. (CLOV), filed an amended Form 4 to update his beneficial ownership.
- The amendment clarifies the achievement of 379,867 performance-based restricted stock units (RSUs) awarded on October 31, 2023, with one-half vesting and settling on September 13, 2024.
- The remaining one-half of these performance-based RSUs are scheduled to vest on October 31, 2025, contingent on continued employment.
- The filing also details a future disposition of 48,305 shares of Class A Common Stock on July 18, 2025, to cover tax obligations upon the vesting of time-based RSUs granted on July 18, 2022.
- After the September 13, 2024 transaction, beneficial ownership stands at 2,544,743 shares, which will adjust to 2,496,438 shares after the July 18, 2025 tax withholding.
Sentiment
Score: 7
Explanation: The filing indicates the achievement of performance-based compensation targets, which is a positive signal regarding the company's performance and the executive's contribution.
Positives
- The amendment confirms the achievement of the full number of performance-based restricted stock units, indicating that the underlying performance conditions were met.
Future Outlook
The filing indicates future vesting events for restricted stock units, with remaining performance-based RSUs vesting on October 31, 2025, and time-based RSUs continuing to vest quarterly until July 18, 2026, subject to continued employment.
Management Comments
- The amendment was filed to reflect the full number of restricted stock units that were achieved, indicating successful performance against set targets.
Industry Context
This filing is a routine disclosure of executive compensation and insider stock ownership changes, which is common across all publicly traded companies and does not inherently reflect broader industry trends or competitive dynamics.
Stakeholder Impact
- Shareholders may view the achievement of performance-based RSUs positively, as it suggests the company met certain internal performance metrics tied to executive compensation.
Next Steps
- Remaining one-half of performance-based restricted stock units to vest on October 31, 2025.
- Further quarterly vesting installments of time-based restricted stock units until July 18, 2026.
Key Dates
| Date | Description |
|---|---|
| 07/18/2022 | Original grant date of time-based restricted stock units (RSUs) to the Reporting Person. |
| 10/31/2023 | Grant date of performance-based restricted stock units (RSUs). |
| 09/13/2024 | Vesting and settlement date for one-half of the earned performance-based restricted stock units. |
| 09/17/2024 | Date of original Form 4 filing. |
| 07/18/2025 | Future vesting date for 6.25% of original time-based RSUs, with shares withheld for tax obligations. |
| 07/22/2025 | Signature date on the amended filing by attorney-in-fact. |
| 10/31/2025 | Future vesting date for the remaining one-half of performance-based restricted stock units. |
| 07/18/2026 | Final vesting date for time-based restricted stock units. |
Recommendation
holdThis Form 4/A filing primarily details changes in an executive's beneficial ownership due to RSU vesting and tax withholding. While the achievement of performance-based RSUs is a positive indicator of internal performance, this type of routine compensation disclosure does not provide sufficient strategic or financial data to warrant a 'buy' or 'sell' recommendation. It is a standard transparency filing for insider transactions.
Keywords
Clover Health, CLOV, SEC filing, Form 4, insider transaction, restricted stock units, RSU, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.